PMID- 25842373
OWN - NLM
STAT- MEDLINE
DCOM- 20160209
LR  - 20150513
IS  - 1872-6240 (Electronic)
IS  - 0006-8993 (Linking)
VI  - 1610
DP  - 2015 Jun 12
TI  - ERV enhances spatial learning and prevents the development of infarcts, 
      accompanied by upregulated BDNF in the cortex.
PG  - 110-23
LID - S0006-8993(15)00277-2 [pii]
LID - 10.1016/j.brainres.2015.03.042 [doi]
AB  - PURPOSES: An anti-allergic and analgesic drug, "an extract derived from the 
      inflamed cutaneous tissue of rabbits inoculated with vaccinia virus (ERV)", has 
      been used in medical practice in Japan and some other countries. We examined the 
      effect of ERV, prior to induction of ischemia, on the development of cerebral 
      infarction, on learning and memory, or on brain-derived neurotrophic factor 
      (BDNF) levels in C57BL/6J mice. METHODS: Following oral administration of ERV 
      (the same in humans: x1) or vehicle, daily for three consecutive weeks, temporary 
      focal ischemia was induced by the three vessel occlusion technique. In the other 
      group of animals, after daily ERV (Low: x1; Med: x3, or High dose: x9) or vehicle 
      administration for three weeks, we performed a quantitative assessment of spatial 
      learning or intracerebral BDNF levels. RESULTS: The volumes of infarcted lesions, 
      brain edema and the extent of the neurological deficits were significantly 
      reduced in the ERV-treated group. ERV treatment also enhanced spatial learning, 
      accompanied by upregulated BDNF in the cortex. CONCLUSIONS: Daily oral intake of 
      ERV, at a clinically relevant dose, protects the brain from ischemic stroke, and 
      also enhances the learning function in normal mice. As millions of people are 
      currently taking the drug safely, and have been for many years in some cases, 
      there is a need to test the inhibitory actions of the drug on progressive 
      dementia encountered in humans with recurrent ischemic attacks or Alzheimer's 
      disease.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Nakajo, Yukako
AU  - Nakajo Y
AD  - Laboratory of Neurology and Neurosurgery, Research Institute, National Cerebral 
      and Cardiovascular Center, Suita 565-8565, Osaka, Japan; Research Laboratory, 
      Rakuwa-kai Otowa Hospital, Kyoto, Japan.
FAU - Yang, Dong
AU  - Yang D
AD  - Laboratory of Neurology and Neurosurgery, Research Institute, National Cerebral 
      and Cardiovascular Center, Suita 565-8565, Osaka, Japan; Department of 
      Neurosurgery, Hospital, National Cerebral and Cardiovascular Center, Suita 
      565-8565, Osaka, Japan; Department of Neurosurgery, China-Japan Friendship 
      Hospital, Beijing, PR China.
FAU - Takahashi, Jun C
AU  - Takahashi JC
AD  - Department of Neurosurgery, Hospital, National Cerebral and Cardiovascular 
      Center, Suita 565-8565, Osaka, Japan.
FAU - Zhao, Qiang
AU  - Zhao Q
AD  - Laboratory of Neurology and Neurosurgery, Research Institute, National Cerebral 
      and Cardiovascular Center, Suita 565-8565, Osaka, Japan; Department of 
      Neurosurgery, Hospital, National Cerebral and Cardiovascular Center, Suita 
      565-8565, Osaka, Japan; Department of Neurosurgery, Baoding No.1 Hospital, Hebei, 
      PR China.
FAU - Kataoka, Hiroharu
AU  - Kataoka H
AD  - Department of Neurosurgery, Hospital, National Cerebral and Cardiovascular 
      Center, Suita 565-8565, Osaka, Japan.
FAU - Yanamoto, Hiroji
AU  - Yanamoto H
AD  - Laboratory of Neurology and Neurosurgery, Research Institute, National Cerebral 
      and Cardiovascular Center, Suita 565-8565, Osaka, Japan; Department of 
      Cardiovascular Science, Division of Surgical Medicine, Osaka University Graduate 
      School of Medicine, Suita, Osaka, Japan. Electronic address: 
      hyanamot@res.ncvc.go.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150401
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Nootropic Agents)
RN  - 0 (Polysaccharides)
RN  - 57657-35-9 (neurotropin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Animals
MH  - Brain/*drug effects/metabolism/pathology
MH  - Brain Edema/metabolism/pathology/prevention & control
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Cerebral Infarction/metabolism/pathology/*prevention & control
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Disease Models, Animal
MH  - Exploratory Behavior/drug effects
MH  - Male
MH  - Memory
MH  - Mice, Inbred C57BL
MH  - Motor Activity/drug effects
MH  - Neuroprotective Agents/*pharmacology
MH  - Nootropic Agents/pharmacology
MH  - Polysaccharides/*pharmacology
MH  - Random Allocation
MH  - Spatial Learning/*drug effects
MH  - Stroke/metabolism/pathology/prevention & control
MH  - Up-Regulation/drug effects
OTO - NOTNLM
OT  - BDNF
OT  - Learning and memory
OT  - Neuroprotection
OT  - Neurotrophic factor
OT  - Preclinical study
EDAT- 2015/04/07 06:00
MHDA- 2016/02/10 06:00
CRDT- 2015/04/06 06:00
PHST- 2014/11/29 00:00 [received]
PHST- 2015/03/19 00:00 [revised]
PHST- 2015/03/24 00:00 [accepted]
PHST- 2015/04/06 06:00 [entrez]
PHST- 2015/04/07 06:00 [pubmed]
PHST- 2016/02/10 06:00 [medline]
AID - S0006-8993(15)00277-2 [pii]
AID - 10.1016/j.brainres.2015.03.042 [doi]
PST - ppublish
SO  - Brain Res. 2015 Jun 12;1610:110-23. doi: 10.1016/j.brainres.2015.03.042. Epub 
      2015 Apr 1.